Coenzyme a

Intervention

2 papers2 findings

PubChem ChEBI

1 lab in 1 country

Funders: National Key Project for Synthetic Biology and 4 more

Animals2

Outcomes

Bone mass loss

downin mice1

1 study

Coenzyme a protects against bone mass loss in mice.
“CoA treatment effectively protects against skeletal aging and bone mass loss in aged or estrogen-deficient mouse models.”
Animalsin aged or estrogen-deficient mice
Kindlin-2 functional restoration through methylmalonic acid clearance by coenzyme A counteracts osteoporosis
Molecular therapy : the journal of the American Society of Gene Therapy27 May 2026

Skeletal aging

downin mice1

1 study

Coenzyme a decreases skeletal aging in mice.
“Notably, the endogenous MMA scavenger coenzyme A (CoA), a clinically approved molecule, effectively reverses MMA- and ONP-induced skeletal aging.”
Animalsin MMA- and ONP-treated young mice
Kindlin-2 functional restoration through methylmalonic acid clearance by coenzyme A counteracts osteoporosis
Molecular therapy : the journal of the American Society of Gene Therapy27 May 2026

Latest

67 in 12 months

Stroke5 h

Blood protein linked to lower brain lesion volume

Higher blood levels of the protein cathepsin B were linked to lower lesion volume, with an association estimate of minus 0.09 in 5,260 people.Higher blood levels of the protein cathepsin B were linked to lower lesion volume, with an association estimate of minus 0.09 in 5,260 people.

Cohort study of 5,260 UK Biobank participantsMechanisms

Limit: The postmortem comparison supporting lesion-related cathepsin B changes involved only eight samples

Paper

Preprints.org6 h

Blood Plasma Coenzyme Q₁₀and P-Selectin Are Predictive Factors for Mild Cognitive Dysfunction in Elderly Women

Preprint: cross-sectional study of 45 peopleCognitive dysfunction

Paper

Nutrients12 h

Multidimensional Neuroprotective Effects of Combined Ubisol-Q10 and Ashwagandha (Withania somnifera) in Male and Female 5XFAD Mice

Experiments in miceInterventions

Paper

medRxivYesterday

Part 2 of a 2-part open-label clinical trial evaluating repeated nicotinamide riboside parenteral administration: 90 days of at-home subcutaneous injections

Preprint: non-randomised trial in peopleNicotinamide riboside

Paper

Frontiers in NeurologyYesterday

NAD⁺ signaling in Parkinson's disease: molecular mechanisms and therapeutic perspectives

ReviewParkinson's disease

Paper

medRxiv14 Oct

Part 1 of a 2-part, open-label clinical trial evaluating repeated nicotinamide riboside parenteral administration: 3 consecutive days of intramuscular and subcutaneous injections

Preprint: randomised trial in 39 peopleNicotinamide riboside

Paper

BioFactors2 Oct

Enhanced Extracellular Matrix Synthesis-Related Responses Induced by Ubiquinol-10 Derivatives in Human Dermal Fibroblasts

Experiments in human cellsInterventions

Paper

Aging Cell30 Sep

Dietary CoQ10 ameliorates megakaryocyte dysfunction in aged mice

Male mice treated with CoQ10 for 12 weeks showed enhanced megakaryocyte maturation and polyploidization, accompanied by reduced platelet aggregation and activation.Male mice treated with CoQ10 for 12 weeks showed enhanced megakaryocyte maturation and polyploidization, accompanied by reduced platelet aggregation and activation.

Experiments in miceInterventions

Paper

Antioxidants26 Sep

Oxidative Stress in Vascular Aging: Therapeutic Potential of the Antioxidant Paradox. A State-of-the-Art Review

ReviewInterventions

Paper

Frontiers in Aging26 Sep

Narrative review of intravenous NAD⁺ and NAD⁺ precursors in wellness and translational medicine

ReviewNAD+ precursors

Paper